Hologic, Inc. (HOLX)

Hologic, Inc. (HOLX) Healthcare & Pipeline Overview

Hologic, Inc. is a global leader in women's health, providing innovative diagnostic, imaging, and surgical solutions. With a strong focus on early detection and treatment, Hologic serves a critical need in the healthcare sector, leveraging its diverse product portfolio and international reach to maintain a competitive edge.

What Is the Investment Thesis for HOLX?

Hologic, Inc. presents a compelling investment thesis based on its strong market position in women's health, driven by innovative diagnostic and surgical solutions. The company's diversified product portfolio across diagnostics, breast health, GYN surgical, and skeletal health segments provides resilience and multiple growth avenues. Hologic's focus on early detection and treatment aligns with increasing healthcare awareness and demand for preventative solutions. Key value drivers include sustained revenue growth in the diagnostics segment, particularly from molecular diagnostics and COVID-19 testing, and continued adoption of its advanced breast imaging technologies. The company's gross margin of 52.8% indicates strong pricing power and efficient operations. Upcoming catalysts include new product launches in the GYN surgical segment and expansion into emerging markets. Potential risks include increased competition and regulatory changes impacting medical device approvals.

Based on FMP financials and quantitative analysis

HOLX Key Highlights

• Market Cap of $16.97B reflects Hologic's significant presence in the medical instruments and supplies industry.
• P/E ratio of 31.4 indicates investor confidence in Hologic's earnings potential compared to the industry average.
• Profit Margin of 13.2% demonstrates Hologic's ability to generate profit from its revenue.
• Gross Margin of 52.8% showcases efficient cost management and strong pricing power.
• Beta of 0.70 suggests lower volatility compared to the overall market, making it a relatively stable investment.

Who Are HOLX's Competitors?

HOLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HOLX's Key Strengths?

• Strong market position in women's health.
• Diversified product portfolio across multiple segments.
• Innovative diagnostic and surgical solutions.
• Established global presence.

What Are HOLX's Weaknesses?

• Dependence on specific product lines.
• Exposure to regulatory changes and healthcare reforms.
• Competition from larger medical device companies.
• Potential impact from economic downturns.

What Could Drive HOLX Stock Higher?

• New product launches in the GYN Surgical segment are expected to drive revenue growth in the second half of 2026.
• Continued adoption of 3D mammography systems is expected to increase market share in the Breast Health segment.
• Expansion of molecular diagnostics capabilities will capitalize on the growing demand for infectious disease testing.
• Strategic partnerships in emerging markets are expected to expand Hologic's global reach by Q4 2026.

What Are the Key Risks for HOLX?

• Rich valuation — a P/E of 31.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Insider selling — insiders were net sellers of roughly $17.4M recently.
• Increased competition from larger medical device companies could impact market share.
• Regulatory changes and healthcare reforms could affect product approvals and reimbursement rates.
• Product liability claims could result in financial losses and reputational damage.
• Economic downturns could reduce healthcare spending and impact sales.

What Are the Growth Opportunities for HOLX?

• Expansion of Molecular Diagnostics: Hologic can capitalize on the growing demand for molecular diagnostics by expanding its Aptima assay portfolio. The global molecular diagnostics market is projected to reach $15 billion by 2027, driven by advancements in testing technologies and increasing prevalence of infectious diseases. Hologic's established presence and expertise in this area provide a competitive advantage, enabling it to capture a larger share of the market through new assay development and geographic expansion.
• Growth in Breast Health Segment: The breast health segment offers significant growth potential through the adoption of 3D mammography and minimally invasive biopsy technologies. The global breast cancer diagnostics market is expected to reach $5.5 billion by 2028, fueled by increasing awareness and screening programs. Hologic's advanced imaging systems and biopsy devices position it to benefit from this trend, particularly in regions with growing healthcare infrastructure and rising breast cancer incidence.
• GYN Surgical Innovation: Hologic can drive growth in its GYN surgical segment by introducing innovative solutions for the treatment of abnormal uterine bleeding and uterine fibroids. The global endometrial ablation market is projected to reach $1.2 billion by 2026, driven by the increasing preference for minimally invasive procedures. Hologic's NovaSure and MyoSure systems offer effective and safe alternatives to traditional surgical methods, providing a competitive edge in this market.
• Emerging Markets Expansion: Expanding into emerging markets presents a significant growth opportunity for Hologic. Countries in Asia-Pacific and Latin America are experiencing rapid growth in healthcare spending and increasing demand for advanced medical technologies. Hologic can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets, capitalizing on the growing need for women's health solutions.
• Strategic Acquisitions and Partnerships: Hologic can pursue strategic acquisitions and partnerships to expand its product offerings and market reach. Acquiring companies with complementary technologies or distribution networks can accelerate growth and enhance Hologic's competitive position. For example, acquiring a company specializing in digital pathology could strengthen Hologic's diagnostics segment and provide new revenue streams.

What Opportunities Does HOLX Have?

• Expansion into emerging markets.
• Development of new diagnostic and surgical technologies.
• Strategic acquisitions and partnerships.
• Increasing demand for preventative healthcare solutions.

What Threats Does HOLX Face?

• Increased competition from existing and new players.
• Technological obsolescence.
• Product liability claims.
• Changes in reimbursement policies.

What Are HOLX's Competitive Advantages?

• Strong brand reputation in women's health.
• Extensive portfolio of patented technologies.
• Established relationships with key healthcare providers.
• High switching costs for customers due to specialized equipment and training.

What Does HOLX Do?

Hologic, Inc., founded in 1985 and headquartered in Marlborough, Massachusetts, is a global leader in developing, manufacturing, and supplying healthcare solutions focused on women's health. The company operates through four key segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Hologic's evolution has been marked by continuous innovation in medical technology, addressing critical needs in early detection and treatment. Its diagnostic offerings include the Aptima molecular diagnostic assays, which detect infectious microorganisms, and viral load tests for HIV, Hepatitis C, and Hepatitis B. The company also provides the Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2. Furthermore, Hologic offers the ThinPrep System for cytology applications and the Rapid Fetal Fibronectin Test for assessing preterm birth risk. In the realm of breast health, Hologic provides advanced imaging and analytics, including 2D and 3D digital mammography systems, minimally invasive breast biopsy guidance systems, and ultrasound solutions. The GYN Surgical segment features the NovaSure Endometrial Ablation System for abnormal uterine bleeding and the MyoSure Hysteroscopic Tissue Removal System for removing fibroids and polyps. The Skeletal Health segment includes the Horizon DXA system for bone densitometry and the Fluoroscan Insight FD mini C-arm for minimally invasive orthopedic procedures. Hologic sells its products through direct sales and service forces, as well as through independent distributors and sales representatives across the United States, Europe, the Asia-Pacific, and other international markets.

What Products and Services Does HOLX Offer?

• Develops and manufactures diagnostic products for women's health.
• Offers medical imaging systems, including mammography and ultrasound.
• Provides surgical products for gynecological procedures.
• Specializes in early detection and treatment solutions.
• Offers molecular diagnostic assays to detect infectious microorganisms.
• Provides systems for cytology applications.
• Offers solutions for bone densitometry and minimally invasive orthopedic procedures.

How Does HOLX Make Money?

• Develops and manufactures diagnostic, imaging, and surgical products.
• Sells products through direct sales and service forces.
• Utilizes independent distributors and sales representatives.
• Generates revenue from product sales and service contracts.

What Industry Does HOLX Operate In?

Hologic, Inc. operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced healthcare solutions. The global medical devices market is projected to reach $600 billion by 2025, driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. Hologic's focus on women's health positions it favorably within this market, as women's health remains a critical and growing area of healthcare. Competitors such as ILMN: Illumina, Inc. and SNN: Smith & Nephew plc also operate in this space, but Hologic differentiates itself through its comprehensive suite of diagnostic, imaging, and surgical solutions tailored specifically for women's health needs.

Who Are HOLX's Key Customers?

• Hospitals and clinics
• Diagnostic laboratories
• Physician offices
• Imaging centers

How Hologic, Inc. Is Valued

Hologic, Inc. carries a market capitalization of $16.97B, placing it in the large-cap category. Relative to its peer group, HOLX's quantitative score of 58/100 is below the peer average of 78/100.

Company Profile

Hologic, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Marlborough, US. The company is led by CEO Paul Malenchini. HOLX has traded publicly since 1990.

ROE 11%Key Financial Metrics

Return on equity for Hologic, Inc. stands at 11.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.9%, showing how much profit it generates from its asset base. HOLX trades at a trailing price-to-earnings ratio of 31.36, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 7/9Financial Health

Hologic, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.24 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Hologic, Inc. revenue of about $4.20B for fiscal 2026, with EPS near $4.42. The estimate reflects 12 contributing analysts.

Net sellingInsider Activity

Over the past six months, Hologic, Inc. insiders filed 30 SEC Form 4 transactions — 26 sales and 4 purchases. On net that is roughly 423K shares disposed (about $17.4M), a signal worth weighing alongside the fundamentals.

HOLX Financials

HOLX Latest News

HOLX Analyst Consensus

HOLX MoonshotScore

What Investors Ask About Hologic, Inc. (HOLX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources